Please assess the completion status of the following clinical trial:

Trial Title: Major Depressive Disorder: Early Prediction of Non-response to Antidepressant Therapy Via a Mobile Digital Scale

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 70 Years~* Diagnostic and Statistical Manual of Mental Disorders-5 criteria for MDD~* Score \> 21 on HDRS-17~* Initiation of an antidepressant treatment for the current episode (first line or second line treatment, ...)~* Ability to use a mobile application~* Agreement to use the study mobile if he/she does not own an iPhone 5 or newer~* Enrolled in or benefiting of a Social Security program~* Having read the information sheet and signed the informed consent form~Non inclusion Criteria:~* Serious suicidal risk, identified by the Mini International Neuropsychiatric Interview (MINI)~* Perinatal depression~* Seasonal affective disorder~* Psychiatric comorbidities: bipolar disorder, obsessive-compulsive disorder, post-traumatic stress, psychotic disorder, anorexia nervosa, bulimia nervosa, personality disorder identified by the MINI questionnaire~* Alcohol addiction or abuse, identified by the MINI questionnaire~* Substance related disorders non-alcoholic addiction or abuse (opioids, cocaine, cannabis, sedatives, stimulants, hallucinogens, inhalants, solvents), identified by the MINI questionnaire~* Under neurostimulation (\< 6 months before inclusion day)~* Patient under Temporary Use Authorisation (TUA)~* Patients with Monoamine Oxidase Inhibitor (MAOIs), tricyclic antidepressant~* Patient with electroconvulsive therapy (ECT) history for current episode~* Patient with a somatic pathology~* Scheduled hospitalization for more than 7 days~* Antecedent of major head trauma~* Seizures~* Systemic medical diseases that are likely to affect cognitive functioning~* Pregnant and nursing women~* Wearers of pacemakers, implantable defibrillators~* Subjects not proficient in French~* Person under guardianship or curators~* Illiterate subjects~* Participation to another interventional clinical trial (category 1)~Exclusion criteria:~* Serious suicidal risk, according to clinician's judgement~* Discontinuation or change of AD treatment before 4 weeks after the dose initiation in the phase 1 and 2~* Initiation of a structured psychotherapy or neurostimulation~* Initiation of treatment with MAOIS~* Introduction of benzodiazepines at regular doses. Limited use (≤7 consecutive days or several periods of ≤3 consecutive days) is authorized~* Alcohol and substances abuse related disorders (opioids, cocaine, cannabis, sedatives, stimulants, hallucinogens, inhalants, solvents), according to clinician's judgement.~* Patient under Temporary Use Authorisation (TUA)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Major Depressive Disorder (Type: EXPERIMENTAL): Patients will be followed for 12 weeks. Hospital visits will be made at week 2 and week 6 (Phase1) as well as week 8 and week 12 (Phase 2).~At the end of phase 1 if the patient is considered as an responder he will make one more visit at week 12.~If the patient is considered as non-responder, he will make 2 other visits: at week 8 and week 12.~Between each visit, the patient will perform REDRESS application assessments every day for My daily survey and every 3 days for the other assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).